This is a summary of the European public assessment report (EPAR) for MicardisPlus. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for MicardisPlus.
Therapeutic Indication
Treatment of essential hypertension. MicardisPlus fixed\-dose combination (40 mg telmisartan / 12\.5 mg hydrochlorothiazide, 80 mg telmisartan / 12\.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone. MicardisPlus fixed\-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on MicardisPlus (80 mg telmisartan / 12\.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.
Therapeutic Area (MeSH)
ATC Code
C09DA07
ATC Item
N/A
Pharmacotherapeutic Group
Agents acting on the renin-angiotensin system
Active Substance (Summary)
INN / Common Names
EMA Name
MicardisPlus
Medicine Name
MicardisPlus
Aliases
N/ANo risk management plan link.
